Senior Correspondent, London
Ben's Feed
Nov 13, 2014

AstraZeneca developing reversal agent for heart drug Brilinta

LONDON, Nov 13 (Reuters) – AstraZeneca is developing
an antibody treatment to reverse the blood-thinning effect of
its heart drug Brilinta in rare emergency situations, such as
urgent surgery or in the event of major bleeding.

The move could give Brilinta an edge among drugs that block
platelets in the blood, since there are no approved products to
counteract their effects. Because they reduce clotting, the
drugs can cause problems if doctors need to operate suddenly.

Nov 11, 2014
Nov 10, 2014
Nov 10, 2014
Nov 10, 2014
Nov 7, 2014
Nov 6, 2014
Nov 6, 2014
Nov 6, 2014

EU scheme commits $350 mln for research on Ebola vaccines, tests

LONDON, Nov 6 (Reuters) – The Europe Union and drugmakers
pledged on Thursday to invest 280 million euros ($350 million)
in Ebola research, with the lion’s share going to the testing
and manufacture of potential vaccines.

The funding will go to projects backed by the Innovative
Medicines Initiative (IMI), a public-private scheme jointly paid
for by the European Commission and the pharmaceuticals industry.

Nov 6, 2014

EU scheme commits $350 mln to research Ebola vaccines and tests

LONDON, Nov 6 (Reuters) – The Europe Union and drugmakers
pledged on Thursday to invest 280 million euros ($350 million)
into Ebola research, with the lion’s share going to fast-track
the testing and manufacture of potential vaccines.

The funding will go to projects backed by the Innovative
Medicines Initiative (IMI), a public-private scheme jointly paid
for by the European Commission and the pharmaceuticals industry.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben